VERTEX PHARMACEUTICALS INC's ticker is VRTX and the CUSIP is 92532F100. A total of 501 filers reported holding VERTEX PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 1.86 and the average weighting 0.2%.
About VERTEX PHARMACEUTICALS INC
Vertex Pharmaceuticals Inc. is a biotechnology company that specializes in developing treatments for serious diseases such as cystic fibrosis, sickle cell disease, and beta-thalassemia. The company has been making significant strides in the field of biotechnology, and its innovative approach to drug development has earned it a reputation as a leader in the industry.
Vertex Pharmaceuticals has a strong pipeline of drugs in development, and its most promising product is Trikafta, a treatment for cystic fibrosis. Trikafta has been shown to be highly effective in clinical trials, and it has the potential to transform the lives of people living with cystic fibrosis. The drug has already been approved by the FDA, and it is expected to generate significant revenue for the company in the coming years.
Vertex Pharmaceuticals has a talented team of scientists and researchers who are dedicated to developing new treatments for serious diseases. The company has a strong track record of success, and it is well-positioned to continue to grow and expand in the years ahead.
Investors who are interested in biotechnology stocks should consider adding Vertex Pharmaceuticals to their portfolio. The company has a strong pipeline of drugs in development, and its innovative approach to drug development has the potential to generate significant returns for investors. With its talented team of scientists and researchers, Vertex Pharmaceuticals is well-positioned to continue to lead the way in the field of biotechnology.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $25,199,866 | +7.9% | 53,763 | -3.8% | 0.05% | +6.1% |
| Q1 2024 | $23,357,143 | -15.6% | 55,877 | -17.8% | 0.05% | -22.2% |
| Q4 2023 | $27,672,994 | +21.4% | 68,011 | +3.8% | 0.06% | +1.6% |
| Q3 2023 | $22,789,575 | +2.9% | 65,536 | +4.2% | 0.06% | +6.9% |
| Q2 2023 | $22,142,882 | +43.9% | 62,922 | +28.8% | 0.06% | +52.6% |
| Q1 2023 | $15,390,225 | +88415.7% | 48,847 | -18.9% | 0.04% | -17.4% |
| Q4 2022 | $17,387 | -99.9% | 60,207 | +7.2% | 0.05% | -4.2% |
| Q3 2022 | $16,258,000 | +4.1% | 56,152 | +1.3% | 0.05% | +11.6% |
| Q2 2022 | $15,624,000 | -3.2% | 55,445 | -10.3% | 0.04% | +7.5% |
| Q1 2022 | $16,135,000 | -3.4% | 61,809 | -18.7% | 0.04% | +2.6% |
| Q4 2021 | $16,697,000 | +24.1% | 76,028 | +2.5% | 0.04% | +14.7% |
| Q3 2021 | $13,458,000 | +6.7% | 74,190 | +18.6% | 0.03% | +3.0% |
| Q2 2021 | $12,608,000 | +6.2% | 62,529 | +13.2% | 0.03% | 0.0% |
| Q1 2021 | $11,874,000 | -3.5% | 55,253 | +6.2% | 0.03% | -10.8% |
| Q4 2020 | $12,299,000 | +9.1% | 52,045 | +25.6% | 0.04% | -5.1% |
| Q3 2020 | $11,270,000 | +11.4% | 41,429 | +18.9% | 0.04% | +2.6% |
| Q2 2020 | $10,119,000 | +2.0% | 34,854 | -16.5% | 0.04% | -15.6% |
| Q1 2020 | $9,923,000 | -0.2% | 41,722 | -8.1% | 0.04% | +25.0% |
| Q4 2019 | $9,941,000 | +75.8% | 45,392 | +36.0% | 0.04% | +63.6% |
| Q3 2019 | $5,654,000 | -3.3% | 33,375 | +4.7% | 0.02% | -4.3% |
| Q2 2019 | $5,844,000 | +19.1% | 31,866 | +19.5% | 0.02% | -20.7% |
| Q1 2019 | $4,906,000 | +41.7% | 26,672 | +27.6% | 0.03% | +20.8% |
| Q4 2018 | $3,463,000 | +356.9% | 20,900 | +428.7% | 0.02% | +380.0% |
| Q3 2018 | $758,000 | -14.8% | 3,953 | -24.5% | 0.01% | -16.7% |
| Q2 2018 | $890,000 | +9.5% | 5,237 | +5.2% | 0.01% | 0.0% |
| Q1 2018 | $813,000 | +32.8% | 4,979 | +21.9% | 0.01% | +50.0% |
| Q4 2017 | $612,000 | +46.1% | 4,086 | +48.3% | 0.00% | +33.3% |
| Q3 2017 | $419,000 | +22.5% | 2,755 | +3.9% | 0.00% | 0.0% |
| Q2 2017 | $342,000 | +48.1% | 2,651 | +25.8% | 0.00% | +50.0% |
| Q1 2017 | $231,000 | -88.1% | 2,108 | -91.4% | 0.00% | -89.5% |
| Q1 2016 | $1,941,000 | +84.9% | 24,421 | +192.7% | 0.02% | +72.7% |
| Q4 2015 | $1,050,000 | +41.3% | 8,343 | +16.9% | 0.01% | +37.5% |
| Q3 2015 | $743,000 | -16.7% | 7,136 | -1.2% | 0.01% | -11.1% |
| Q2 2015 | $892,000 | – | 7,221 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Copernicus Capital Management, LLC | 52,244 | $8,515,000 | 6.78% |
| BB BIOTECH AG | 1,475,445 | $240,468,000 | 6.65% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 68,222 | $11,119,000 | 4.34% |
| Tekla Capital Management LLC | 614,084 | $100,083,000 | 3.89% |
| Orbimed Advisors | 1,854,600 | $302,263,000 | 3.75% |
| Odey Holdings AG | 276 | $45,000 | 3.56% |
| Signition LP | 17,507 | $2,853,000,000 | 3.47% |
| Eversept Partners, LP | 44,822 | $7,305,090 | 3.39% |
| Crawford Lake Capital Management, LLC | 89,229 | $14,543,000 | 3.10% |
| ATALANTA SOSNOFF CAPITAL, LLC | 564,783 | $92,049,000 | 3.07% |